The Motley Fool Investing Philosophy: We generally recommend investors buy shares of at least 25 stocks and hold them for at least 5 years. Learn More
| 1 Year | 5 Year | 5 Year Annualized | Since IPO | |
|---|---|---|---|---|
| XBIT | -67.55% | -85.95% | -32.46% | -88% |
| S&P | +13.96% | +91.24% | +13.85% | +225% |
XBiotech, Inc. is a biopharmaceutical company, which engages in the development and commercialization of therapeutic antibodies. Its product pipeline includes oncology, infectious diseases, dermatology and inflammatory disorders. The company was founded by John Simard on March 22, 2005 and is headquartered in Austin, TX.
The company's offer to buy back shares was overtendered, resulting in a prorated deal.
The company is offering to buy back shares from investors at a big premium.
| Q2 2025 | YOY Change | |
|---|---|---|
| Revenue | $0.00M | 0.0% |
| Gross Profit | -$0.44M | -0.9% |
| Market Cap | $90.55M | -42.2% |
| Market Cap / Employee | $0.98M | -42.2% |
| Employees | 92 | 0.0% |
| Net Income | -$1.76M | 86.5% |
| EBITDA | -$5.90M | 59.4% |
Currently no data to display
Currently no data to display.
Currently no data to display.
| Q2 2025 | YOY Change | |
|---|---|---|
| Net Cash | $152.94M | -18.9% |
| Inventory | 0 | 0.0% |
| Q2 2025 | YOY Change | |
|---|---|---|
| Long Term Debt | $0.00M | 0.0% |
| Short Term Debt | $0.00M | -100.0% |
| Q2 2025 | YOY Change | |
|---|---|---|
| Return On Assets | -14.29% | 1.2% |
| Return On Invested Capital | -11.15% | -21.9% |
| Q2 2025 | YOY Change | |
|---|---|---|
| Free Cash Flow | -$6.04M | 49.7% |
| Operating Free Cash Flow | -$5.99M | 47.4% |
| Metric | Q3 2024 | Q4 2024 | Q1 2025 | Q2 2025 | YoY Change |
|---|---|---|---|---|---|
| Price to Book | 1.20 | 0.63 | 0.54 | 0.52 | -30.70% |
| Price to Tangible Book Value | 1.20 | 0.63 | 0.54 | 0.52 | -30.70% |
| Enterprise Value to EBITDA | -8.36 | 5.05 | 4.36 | 10.58 | 599.25% |
| Return on Equity | -15.7% | -19.2% | -20.5% | -15.2% | -7.37% |
| Total Debt | $10.00M | $10.25M | $0.00M | $0.00M | - |
No podcast episodes available.
No transcripts available.
Invest better with The Motley Fool. Get stock recommendations, portfolio guidance, and more from The Motley Fool's premium services.
